Cryoport, Inc.
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
About Cryoport
Pharmaceutical Preparations, SIC 2834
Cryoport provides temperature-controlled supply chain solutions for the life sciences industry, focusing on cell and gene therapies. The company operates in two segments: Life Sciences Services and Life Sciences Products. Its services include temperature-sensitive logistics, biostorage, sample management, kitting, labeling, and cryopreservation of cell materials. Its products segment designs and manufactures cryogenic equipment, such as freezers and dewars for biological storage and transit. Cryoport serves biopharmaceutical companies, research and academic institutions, laboratories, fertility clinics, animal health businesses, and government agencies.
The company operates across the Americas, EMEA, and APAC regions. Facilities and supply chain centers are located in places including Houston and San Antonio, Texas, as well as Paris, France, and Liège, Belgium. Cryogenic manufacturing facilities are located in the United States and China. The business supports 760 clinical trials and 20 approved commercial therapies. The provided text does not state the location of corporate headquarters.
Summary of the business section of Cryoport's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cryoport, Inc.
- Headquarters
- Brentwood, TN
- Address
- 112 Westwood Place, Suite 350 37027
- Phone
- (949) 232-1900
- Website
- cryoportinc.com
- Employees
- 738, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Nashville, Tennessee
Stock & identifiers
- Ticker
- CYRX
- Exchange
- Nasdaq
- IPO date
- Aug 22, 2005
- Shares outstanding
- 51M, Jul 31, 2026
- Public float
- $400.00M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-12 reverse, May 19, 2015; 1-for-12 reverse, May 19, 2015; 1-for-10 reverse, Feb 5, 2010
- SEC CIK
- 1124524
- CUSIP
- 229050307
- ISIN
- US2290503075
- LEI
- 9845004D8538BT8JF626
- EIN
- 88-0313393
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jerrell Shelton | President, CEO, Director | 1,213,128 |
| Edward J. Zecchini | Chief Digital and Tech Officer | 143,319 |
| Robert Stefanovich | Chief Financial Officer | 109,850 |
| Mark W. Sawicki | Chief Scientific Officer | 102,356 |
| Linda Baddour | Director | 68,099 |
| Robert J. Hariri | Director | 61,625 |
| Daniel M. Hancock | Director | 69,052 |
| Ramkumar Mandalam | Director | 67,894 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Shelton | $2.38M | $2.65M | $1.06M | $22 | $105 |
| FY2024 Mr.Shelton | $1.87M | $962.52K | $979.44K | $18 | $101 |
| FY2023 Mr.Shelton | $2.24M | $1.50M | $1.04M | $35 | $104 |
| FY2022 Mr.Shelton | $2.49M | -$7.38M | $1.11M | $40 | $107 |
| FY2021 Mr.Shelton | $5.13M | $9.64M | $1.92M | $135 | $140 |
| FY2020 Mr.Shelton | $5.48M | $15.79M | $1.81M | $267 | $136 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 738 employees: 684 full-time, 8 part-time, and 46 temporary, of which 448 are located in the Americas, 148 in EMEA and 142 in APAC.”
Corporate history
Events identified from SEC filings